Skip Nav Destination
Issues
ARTICLE
The Effects of the Novel, Reversible Epidermal Growth Factor Receptor/ErbB-2 Tyrosine Kinase Inhibitor, GW2016, on the Growth of Human Normal and Tumor-derived Cell Lines in Vitro and in Vivo
David W. Rusnak; Karen Lackey; Karen Affleck; Edgar R. Wood; Krystal J. Alligood; Nelson Rhodes; Barry R. Keith; Doris M. Murray; W. Blaine Knight; Robert J. Mullin; Tona M. Gilmer
Design and Synthesis of Fluoroquinophenoxazines That Interact with Human Telomeric G-Quadruplexes and Their Biological Effects1
Wenhu Duan; Anupama Rangan; Hariprasad Vankayalapati; Mu-Yong Kim; Qingping Zeng; Daekyu Sun; Haiyong Han; Oleg Yu. Fedoroff; David Nishioka; Sun Young Rha; Elzbieta Izbicka; Daniel D. Von Hoff; Laurence H. Hurley
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.